drugset / Trial / NCT01128153

Saxagliptin Triple Oral Therapy

NCT01128153

Phase 3 Completed 257 enrolled AstraZeneca Bristol-Myers Squibb · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether the addition of saxagliptin to a patient's combination treatment of metformin and sulfonylurea for a 24 week period will provide better control of the patient's type 2 diabetes and will be well tolerated.

Timeline

Start
2010-06
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SAXAGLIPTIN ANHYDROUS Small molecule 5 mg Oral